REG - Solvonis Therapeutic - Initiation of AI supported CNS drug discovery

Solvonis TherapeuticsAnnouncement

11/06/2025 07:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250611:nRSK3646Ma&default-theme=true

RNS Number : 3646M  Solvonis Therapeutics PLC  11 June 2025

11 June 2025
Solvonis Therapeutics plc

("Solvonis" or the "Company")

Initiation of artificial intelligence supported CNS drug discovery programme

 

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders,
is pleased to announce the initiation of an artificial intelligence ("AI")
supported drug discovery programme focused on its proprietary central nervous
system ("CNS") compound library.

The library, acquired through the Company's recent acquisition of Awakn Life
Sciences Corp. ("Awakn"), includes multiple patent-pending chemical series
developed through a completed hit-to-lead programme. This body of work
incorporated in silico design, in vitro screening and in vivo
characterisation. The resulting dataset forms a structurally differentiated
early-stage portfolio with therapeutic potential across a range of
neuropsychiatric indications.

The new programme will apply AI and computational modelling techniques to
enable data-driven asset prioritisation, structure-activity relationship
("SAR") analysis and translational hypothesis generation. The objective is to
accelerate the identification and optimisation of high-value development
candidates within the library.

Under the scientific leadership of Professor David Nutt, Solvonis' Chief
Scientific Officer, the AI enabled programme will initially prioritise
indications in depression and stimulant use disorders.

This initiative is distinct from Solvonis' existing preclinical programme,
SVN-SDN-014, which targets post-traumatic stress disorder ("PTSD"). Together,
these efforts comprise a strategically diversified R&D pipeline spanning
late-stage clinical assets in Alcohol Use Disorder, a novel preclinical PTSD
programme and a discovery platform focused on comorbid, high-burden
neuropsychiatric conditions.

Professor David Nutt, Chief Scientific Officer of Solvonis, commented: "The
integration of AI supported analytics into our discovery workflow enhances our
ability to identify high-potential compounds for further development. The
underlying chemistry is robust and scientifically validated, and we believe
this approach will bring forward differentiated candidates in areas of
persistent clinical need."

Anthony Tennyson, Chief Executive Officer of Solvonis, added: "Following the
acquisition of Awakn, we now possess a CNS compound library with strong early
validation. This initiative reflects our strategy to combine capital-efficient
innovation with rigorous translational science as we develop next-generation
therapeutics for depression, addiction, and other high-burden mental health
conditions."

Enquiries:

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

anthony@solvonis.com

Allenby Capital Limited (Financial Adviser and Joint Broker)

Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)

Guy McDougall (Sales & Corporate Broking)

+44 (0) 20 3328 5656

Singer Capital Markets (Joint Broker)

Phil Davies

+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders.
Headquartered in London and listed on the main market of the London Stock
Exchange (transition category), Solvonis is advancing a differentiated
pipeline of repurposed and novel compounds targeting high-burden
neuropsychiatric conditions with significant unmet need.

The Company's lead programs address Alcohol Use Disorder ("AUD") and
Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million
people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in
Phase 3 for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase
2b trial in the US targeting moderate to severe AUD. Solvonis also has a
preclinical PTSD program leveraging novel serotonin-dopamine modulators
designed to enhance pro-social behaviour and long-term outcomes.

In addition, Solvonis is advancing an AI supported discovery platform built on
a proprietary CNS compound library, with initial focus on depression and
stimulant use disorders. This initiative expands the Company's R&D
pipeline into earlier-stage innovation while maintaining strategic focus on
comorbid and underserved neuropsychiatric conditions.

With a capital-efficient model, dual development strategy, and near-term
partnering opportunities, Solvonis is positioned to generate value through
innovation in neuropsychiatry.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDQFLBFEQLFBBV